All In Biotech

Drug Trial Radar · NCT04693234

AdvanTIG-202: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Previously Treated Recurrent or Metastatic Cervical Cancer

Phase 2 Study Investigating Efficacy and Safety of Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody BGB-A1217 in Patients With Previously Treated Recurrent or Metastatic Cervical Cancer

Last checked: Nov 19, 2026Latest source record: Apr 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 178 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

178

Actual

Start

Feb 15, 2021

Primary completion

Jun 16, 2022

Study completion Aug 31, 2023

Sponsor

Lead sponsor
BeiGeneBeOne Medicines (BeiGene) (ONC)
Sponsor type
Industry
First posted
Jan 5, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study tested how well and how safely the drug tislelizumab, given either alone or with another drug called ociperlimab (BGB-A1217), worked in people with cervical cancer that had come back or spread after previous treatments. The study included two groups and took place at multiple medical centers.

Conditions

  • Cervical Cancer

Interventions

  • TislelizumabBiological

    200 mg administered intravenously once every 3 weeks on day 1 of each cycle

  • OciperlimabBiological

    900 mg administered intravenously once every 3 weeks on day 1 of each cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cohort 1: Objective Response Rate (ORR) Assessed by an Independent Review Committee (IRC) in PD-L1-Positive ParticipantsTime frame: Up to the primary efficacy analysis data cut-off date on June 16, 2022, the median follow-up duration was 7.36 months for Cohort 1.
  2. Cohort 1: ORR Assessed by the IRC in All Treated ParticipantsTime frame: Up to the primary efficacy analysis data cut-off date on June 16, 2022, the median follow-up duration was 7.36 months for Cohort 1.

Locations

68 sites in 8 countries. Site status is shown where the registry gives one.

  • "Mhat uni hospital" ood

    Panagyurishte, Bulgaria

  • Complex Oncology Center Rousse Eood

    Rousse, Bulgaria

  • Medical center nadezhda clinical eood

    Sofia, Bulgaria

  • Acibadem city clinic tokuda umhat ead, department of medical oncology

    Sofia, Bulgaria

  • Beijing Cancer Hosptial

    Beijing, China

  • Cancer Hospital Chinese Academy of Medical Sciences

    Beijing, China

  • Linyi Cancer Hospital

    Shandong, China

  • The First Affiliated Hospital of Xiamen University - Oncology

    Xiamen, China

  • Anhui Provincial Cancer Hospital

    Hefei, Anhui, China

  • Chongqing Cancer Hospital

    Chongqing, Chongqing Municipality, China

  • Southwest Hospital

    Chongqing, Chongqing Municipality, China

  • Gansu Provincial Hospital

    Lanzhou, Gansu, China

  • Sun yat-sen memorial hospital, sun yat-sen university (south)

    Guanzhou, Guangdong, China

  • The Tumor Hospital Affiliated to Guangxi Medical University

    Nanning, Guangxi, China

  • Hainan Cancer Hospital

    Haikou, Hainan, China

  • Henan Cancer Hospital - Oncology

    Zhengzhou, Henan, China

  • Hubei Cancer Hospital - Oncology

    Wuhan, Hubei, China

  • Union Hospital of Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • Hunan Cancer Hospital - GCP Office

    Changsha, Hunan, China

  • Xuzhou Cancer Hospital

    Xuzhou, Jiangsu, China

  • The First Affiliated Hospital of Nanchang University Branch Donghu

    Nanchang, Jiangxi, China

  • Jilin Guowen Hospital

    Jilin City, Jilin, China

  • Liaoning Cancer Hospital & Institute - Medical Oncology - Oncology

    Shenyang, Liaoning, China

  • General Hospital of Ningxia Medical University

    Yinchuan, Ningxia, China

  • Qilu Hospital of Shandong University

    Jinan, Shandong, China

  • Obstetrics and Gynecology Hospital of Fudan University

    Shanghai, Shanghai Municipality, China

  • Second Hospital Of Shanxi Medical University

    Taiyuan, Shanxi, China

  • The First Affiliated Hospital of Xi'an Jiaotong University

    Xi’an, Shanxi, China

  • Tianjin Medical University Cancer institute & Hospital

    Tianjin, Tianjin Municipality, China

  • Affiliated Cancer Hospital of Xinjiang Medical University

    Ürümqi, Xinjiang, China

  • The First Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China

  • Szpitale Pomorskie Spółka z ograniczoną odpowiedzialnością

    Gdynia, Poland

  • Przychodnia lekarska komed

    Konin, Poland

  • Arkhangelsk regional clinical oncological dispensary

    Arkhangelsk, Russia

  • State budgetary healthcare institution-chelyabinsk regional clinical center of oncology and nuclear

    Chelyabinsk, Russia

  • State healthcare institution oncologic dispensary no. 2 - health department of krasnodar region

    Krasnodar, Krasnodarskiy Kray, Russia

  • Fsbi of higher education"ogarev mordovia state university"

    Saransk, Mordovia Republic, Russia

  • Oncological Scientific Center LLC

    Pesochny, Sankt-Peterburg, Russia

  • Sbhi of stavropol region "pyatigorsk interdistrict oncologic dispensary"

    Pyatigorsk, Stavropol Kray, Russia

Showing 40 of 68 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.